Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
1984-4-19
|
| pubmed:abstractText |
One hundred patients with non-small cell lung cancer were entered into a randomized evaluation of two schedules of doxorubicin combined with ftorafur, cyclophosphamide, and cisplatin (FACP). Doxorubicin was given either weekly at 20 mg/m2, or every three weeks (standard) at 60 mg/m2. Fifty-two patients were randomized to the FACP/weekly doxorubicin arm and 48 patients to the FACP/standard doxorubicin arm. The FACP/weekly doxorubicin regimen was associated with higher complete and partial remission rates (31% versus 19%), longer response duration (median, 33 versus 21 weeks), and longer survival duration for responders (median, 58 versus 50 weeks). These differences were not significant. Less neutropenia (p = 0.01) and less infectious morbidity (p = 0.05) were observed in the FACP/weekly doxorubicin arm. Twenty-eight patients underwent 35 endomyocardial biopsies to assess doxorubicin-induced cardiotoxicity. Sixteen biopsies were performed in 12 patients receiving cumulative doxorubicin doses ranging from 250 to 1,190 mg/m2 within the FACP/weekly doxorubicin arm. Nineteen biopsies were performed in 16 patients receiving cumulative doxorubicin doses ranging from 250 to 540 mg/m2 within the FACP/standard doxorubicin regimen. The FACP/weekly doxorubicin regimen was associated with significantly lower cardiotoxicity scores (p = 0.01). This study indicates that weekly administered doxorubicin is as effective and less cardiotoxic than the standard schedule.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
0732-183X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
2
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
207-14
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:6321689-Adenocarcinoma,
pubmed-meshheading:6321689-Adult,
pubmed-meshheading:6321689-Aged,
pubmed-meshheading:6321689-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:6321689-Bone Marrow,
pubmed-meshheading:6321689-Carcinoma, Small Cell,
pubmed-meshheading:6321689-Carcinoma, Squamous Cell,
pubmed-meshheading:6321689-Cisplatin,
pubmed-meshheading:6321689-Clinical Trials as Topic,
pubmed-meshheading:6321689-Cyclophosphamide,
pubmed-meshheading:6321689-Dose-Response Relationship, Drug,
pubmed-meshheading:6321689-Doxorubicin,
pubmed-meshheading:6321689-Drug Administration Schedule,
pubmed-meshheading:6321689-Female,
pubmed-meshheading:6321689-Heart,
pubmed-meshheading:6321689-Humans,
pubmed-meshheading:6321689-Lung Neoplasms,
pubmed-meshheading:6321689-Male,
pubmed-meshheading:6321689-Middle Aged,
pubmed-meshheading:6321689-Prospective Studies,
pubmed-meshheading:6321689-Random Allocation,
pubmed-meshheading:6321689-Tegafur
|
| pubmed:year |
1984
|
| pubmed:articleTitle |
Increased therapeutic index of weekly doxorubicin in the therapy of non-small cell lung cancer: a prospective, randomized study.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial
|